BioSpace News Archive

BioCorRx Inc. is pleased to announce that it has completed its clinical trial agreement with Orange County Research Center for its first-in-human clinical trial of BICX104.

Veru Inc. (NASDAQ: VERU) today announced that the Independent Data Monitoring Committee (IDMC) has conducted a planned conditional power analysis of the first 75 randomized patients in the Global Phase 3 COVID-19.

Advanced Oxygen Therapy Inc. announced today a number of significant additions to its Leadership Team, bringing to the company over 100 years of combined strategic experience.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), announces that new research measuring the benefits of the Company’s MyoPro myoelectric orthosis found “statistically significant improvements” in a number of motor function measurements.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2021 fourth quarter and full year ended December 31, 2021 on Thursday, March 3, 2022 before the open of the U.S. financial markets.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced that it has filed an International PCT Application (PCT/US21/65580) entitled TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY (the ‘580 application).

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced that management would present at two upcoming investor conferences in February.

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2021, as well as key clinical and corporate developments.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, reported financial results for the three months ended December 31, 2021 and provided an update on its business.

The surging cases of neurological disorders and traumatic brain injuries are the key factors boosting the global external ventricular drain market growth.